IR-Crizotinib

• UNSPSC Description:

  IR-Crizotinib is a NF-κB-inducing kinase (NIK) inhibitor that crosses the blood-brain barrier and fluorescently localizes intracranial glioblastoma (GBM) in mice (IC50=3.381 μM). IR-Crizotinib is conjugated from the near-infrared dye IR-786 and the NF-κB-inducing kinase (NIK) inhibitor Crizotinib. IR-Crizotinib can effectively inhibit the growth and invasion of glioma in vitro and in vivo and can be used in cancer research[1].

• Target Antigen:

  NF-κB

• Type:

  Reference compound

• Related Pathways:

  NF-κB

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/ir-crizotinib.html

• Solubility:

  10 mM in DMSO

• Smiles:

  NC(C(O[C@@H](C1=C(Cl)C=CC(F)=C1Cl)C)=C2)=NC=C2C3=CN(N=C3)C4CCN(C5=C(/C=C/C6=[N+](C)C(C=CC=C7)=C7C6(C)C)CCC/C5=C\C=C8C(C)(C)C(C=CC=C9)=C9N/8C)CC4.[I-]

• Molecular Weight:

  1024.87

• References & Citations:

  [1]Pflug KM, et al. Cyanine Dye Conjugation Enhances Crizotinib Localization to Intracranial Tumors, Attenuating NF-κB-Inducing Kinase Activity and Glioma Progression. Mol Pharm. 2023 Nov 8.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  No Development Reported

• CAS Number:

  2387927-74-2